Elicio Therapeutics, Inc. Common Stock (ELTX) is a publicly traded Healthcare sector company. As of July 28, 2026, ELTX trades at $3.04 with a market cap of $78.79M and a P/E ratio of -1.17. ELTX moved +0.00% today. Year to date, ELTX is -62.31%; over the trailing twelve months it is -69.67%. Its 52-week range spans $2.66 to $16.00. Analyst consensus is strong buy with an average price target of $20.67. Rallies surfaces ELTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Elicio Secures Undisclosed Funding After Phase II Trial Miss: After its Phase II trial failed to meet primary endpoints, Elicio secured an undisclosed capital infusion in early July to extend its cash runway. The funding will support continued development of its lead immunotherapy candidate.
| Metric | Value |
|---|---|
| Price | $3.04 |
| Market Cap | $78.79M |
| P/E Ratio | -1.17 |
| EPS | $-2.58 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.00 |
| 52-Week Low | $2.66 |
| Volume | 186.46K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-39.57M |
| Gross Margin | 0.00% |
4 analysts cover ELTX: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.67.